PureTech Health plc (PRTC.L)
PureTech Health is a UK-listed biotherapy creator building a whole stable of experimental medicines through different spin-out ventures.
Is PureTech Health plc a good stock for a UK beginner?
The honest version: PureTech Health is a UK-listed biotherapy creator building a whole stable of experimental medicines through different spin-out ventures.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Multiple spin-out therapies reach the market successfully
Key therapies fail safety checks and capital is depleted
What does PureTech Health plc do?
Imagine a bustling scientific incubator that invents novel treatments for serious conditions, then sets them up as independent companies to test and grow. PureTech makes its money by discovering these breakthrough health ideas and retaining stakes in the resulting biotech firms. The crucial element to keep an eye on is how well these various scientific projects progress through clinical trials without running out of cash.
On our factor screen it looks strongest on value and momentum, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- !Revenue slipped about 38% over the year
- !Thin profits - turns only about 0% of sales into profit
- Diverse portfolio of multiple independent biotech ventures spreading the scientific risk
- Asset-backed valuation close to book value with a manageable price-to-book ratio
- Experienced scientific leadership team with a track record of founding novel therapies
- Quality screens low (15/100)
- Growth screens low (0/100)
- Momentum screens low (18/100)
- Income screens low (9/100)
- High dependence on the success of complex clinical trials
What do PureTech Health plc's numbers mean?
Does PureTech Health plc pay a dividend?
No - PureTech Health plc doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does PureTech Health plc report earnings, and how did recent quarters go?
PureTech Health plc is next scheduled to report on about 2026-08-27 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for PureTech Health plc?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of PureTech Health plc?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Diverse portfolio of multiple independent biotech ventures spreading the scientific risk
- Asset-backed valuation close to book value: A company's net assets - what it owns minus what it owes - per share. Price-to-book compares the share price to this figure. with a manageable price-to-book: The share price versus the company's net assets per share (its book value). Under 1 can look cheap, though it varies a lot by industry. ratio
- Experienced scientific leadership team with a track record of founding novel therapies
- Currently unprofitable with negative return on equity: How much profit the company makes for each £1 shareholders have put in. Higher usually means a more efficient business.
- Recent drop in annual revenue shows unpredictable income streams
- No dividend paid to shareholders
- High dependence on the success of complex clinical trials
- Volatile share price influenced heavily by fickle biotech sentiment
- Risk of cash burn if portfolio companies require further funding
The write-up's own warning lights — if these start happening, the case above changes.
- Consistent generation of positive net income across the group
- Permanent setbacks or halts across all major clinical programmes
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.